High Response Rate for Treatment With Gemtuzumab Ozogamicin and Cytarabine in Elderly Patients With Acute Myeloid Leukemia and Favorable and Intermediate-I Cytogenetic Risk
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology,Hematology
Reference16 articles.
1. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia;Kantarjian;Blood,2010
2. Acute myeloid leukemia and myelodysplastic syndromes in older patients;Estey;J Clin Oncol,2007
3. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry;Juliusson;Blood,2009
4. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse;Sievers;J Clin Oncol,2001
5. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence;Larson;Cancer,2005
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Molecular mechanism of α-Hederin in tumor progression;Biomedicine & Pharmacotherapy;2024-01
2. Basic research on curcumin in cervical cancer: Progress and perspectives;Biomedicine & Pharmacotherapy;2023-06
3. Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2);Indian Journal of Hematology and Blood Transfusion;2015-02-01
4. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials;Annals of Oncology;2014-02
5. De novo AML patients with favourable–intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened “GO question”;Annals of Hematology;2013-05-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3